The FDA has accepted the resubmission of a BLA for odronextamab for the treatment of patients with relapsed/refractory ...

Oncology nurses and APPs play a key role in educating patients on BREAKWATER study findings and their impact on BRAF-mutant ...

Axel Stuart Merseburger, MD, PhD, explained that with TKIs like axitinib, it is necessary for oncology nurses to spend time ...

Oncology nurses are familiar with the concept of financial toxicity, which refers to the significant financial burden cancer ...

Hazards of the LA wildfires necessitate awareness that first responders and those central to the fires may be at risk for ...

The FDA approved tislelizumab-jsgr (Tevimbra) with platinum chemotherapy as a first-line treatment for adults with ...

Key opinion leaders explore approaches to dose modifications or treatment pauses due to side effects, including examples ...

One of the hardest lessons learned occurred after I inadvertently failed at communication and education before transferring a ...

Staying up to date with data from trials and information from organizations dedicated to cancer research is crucial for oncology nurses and APPs.

Patients who receive certain cancer treatments are at greater risk of secondary malignancies and must be educated accordingly ...

Real-World Data Back First-Line Avelumab and Axitinib in Advanced RCC ...

For patients with relapsed BRCA-mutated ovarian carcinoma, rucaparib produced a median OS of 19.4 months vs 25.4 months with ...